Sergio Martinez-Hervas1, Rafael Carmena2, Juan F Ascaso2, Jose T Real2, Luis Masana3, Miguel Catalá2, Joan Vendrell4, José Antonio Vázquez5, Sergio Valdés6, Inés Urrutia7, Federico Soriguer6, Manuel Serrano-Rios8, Gemma Rojo-Martínez6, Gemma Pascual-Manich9, Emilio Ortega10, Inmaculada Mora-Peces11, Edelmiro Menéndez12, Maria T Martínez-Larrad8, Alfonso López-Alba13, Ramón Gomis14, Albert Goday15, Juan Girbés16, Sonia Gaztambide7, Josep Franch17, Elías Delgado12, Conxa Castell18, Luis Castaño7, Roser Casamitjana19, Alfonso Calle-Pascual20, Elena Bordiú21. 1. Service of Encodrinology and Nutrition, Hospital Cliníco Universitario de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria HCUV-INCLIVA, Spain; Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain. Electronic address: Sergio.martinez@uv.es. 2. Service of Encodrinology and Nutrition, Hospital Cliníco Universitario de Valencia, Valencia, Spain; Instituto de Investigación Sanitaria HCUV-INCLIVA, Spain; Department of Medicine, University of Valencia, Valencia, Spain; CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain. 3. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Vascular Medicine and Metabolism Unit, Research Unit on Lipids and Atherosclerosis, Sant Joan University Hospital, Universitat Rovira i Virgili, IISPV, Reus, Tarragona, Spain. 4. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Department of Endocrinology and Nutrition, Hospital Universitario Joan XXIII, Institut d'Investigacions Sanitàries Pere Virgili, Tarragona, Spain. 5. Diabetes National Plan, Ministry of Health, Madrid, Spain. 6. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Department of Endocrinology and Nutrition, Hospital Universitario Carlos Haya, Málaga, Spain. 7. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Diabetes Research Group, Hospital Universitario de Cruces, UPV-EHU, Baracaldo, Vizcaya, Spain. 8. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Lipids and Diabetes Laboratory, Hospital Universitario S. Carlos de Madrid, Madrid, Spain. 9. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. 10. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Canarian Health Service, Tenerife, Spain. 11. Canarian Health Service, Tenerife, Spain. 12. Department of Endocrinology and Nutrition, Hospital Central de Asturias, Oviedo, Spain. 13. Spanish Diabetes Society, Madrid, Spain. 14. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Endocrinology and Diabetes Unit, Hospital Clínic de Barcelona, Universitat de Barcelona (UB), Barcelona, Spain. 15. Department of Endocrinology and Nutrition, Hospital del Mar, Barcelona, Spain. 16. Diabetes Unit, Hospital Arnau de Vilanova, Valencia, Spain. 17. EAP Raval Sud, Institut Català de la Salut, Red GEDAPS, Primary Care, Unitat de Suport a la Recerca (IDIAP-Fundació Jordi Gol), Barcelona, Spain. 18. Public Health Division, Department of Health, Autonomous Government of Catalonia, Barcelona, Spain. 19. CIBER de Diabetes y Enfermedades Metabólicas asociadas (CIBERDEM), Spain; Biomedic Diagnostic Centre University, Hospital Clínic, Barcelona, Spain. 20. Department of Endocrinology and Nutrition, Hospital Universitario San Carlos, Madrid, Spain. 21. Laboratorio de Endocrinología, Hospital Universitario S. Carlos de Madrid, Spain.
Abstract
INTRODUCTION: Dyslipidemia is a significant contributor to the elevated CVD risk observed in type 2 diabetes mellitus. We assessed the prevalence of dyslipidemia and its association with glucose metabolism status in a representative sample of the adult population in Spain and the percentage of subjects at guideline-recommended LDL-C goals. MATERIAL AND METHODS: The di@bet.es study is a national, cross-sectional population-based survey of 5728 adults. RESULTS: A total of 4776 subjects were studied. Dyslipidemia was diagnosed in 56.8% of subjects; only 13.2% of subjects were treated with lipid lowering drugs. Lipid abnormalities were found in 56.8% of Spanish adults: 23.3% with high LDL-C, 21.5% high TG, 35.8% high non-HDL-C, and 17.2% low HDL-C. Most normal subjects showed an LDL-C ≤ 3.36 mmol/l. Pre-diabetics presented similar proportion when considering a goal of 3.36 mmol/l, but only 35% of them reached an LDL-C goal ≤ 2.6 mmol/l. Finally, 45.3% of diabetics had an LDL-C ≤ 2.6 mmol/l, and only 11.3% achieved an LDL-C ≤ 1.8 mmol/l. CONCLUSIONS: Our study demonstrates a high prevalence of dyslipidemia in the adult Spanish population, and a low use of lipid-lowering drugs. Moreover, the number of subjects achieving their corresponding LDL-C goal is small, particularly in subjects at high cardiovascular risk, such as diabetics.
INTRODUCTION:Dyslipidemia is a significant contributor to the elevated CVD risk observed in type 2 diabetes mellitus. We assessed the prevalence of dyslipidemia and its association with glucose metabolism status in a representative sample of the adult population in Spain and the percentage of subjects at guideline-recommended LDL-C goals. MATERIAL AND METHODS: The di@bet.es study is a national, cross-sectional population-based survey of 5728 adults. RESULTS: A total of 4776 subjects were studied. Dyslipidemia was diagnosed in 56.8% of subjects; only 13.2% of subjects were treated with lipid lowering drugs. Lipid abnormalities were found in 56.8% of Spanish adults: 23.3% with high LDL-C, 21.5% high TG, 35.8% high non-HDL-C, and 17.2% low HDL-C. Most normal subjects showed an LDL-C ≤ 3.36 mmol/l. Pre-diabetics presented similar proportion when considering a goal of 3.36 mmol/l, but only 35% of them reached an LDL-C goal ≤ 2.6 mmol/l. Finally, 45.3% of diabetics had an LDL-C ≤ 2.6 mmol/l, and only 11.3% achieved an LDL-C ≤ 1.8 mmol/l. CONCLUSIONS: Our study demonstrates a high prevalence of dyslipidemia in the adult Spanish population, and a low use of lipid-lowering drugs. Moreover, the number of subjects achieving their corresponding LDL-C goal is small, particularly in subjects at high cardiovascular risk, such as diabetics.
Authors: Ana Cecilia Cepeda-Nieto; María Teresa Esquivel-Contreras; Francisco Duran-Iñiguez; Mauricio Andrés Salinas-Santander; Hugo Leonid Gallardo-Blanco; Sandra Cecilia Esparza-González; Alejandro Zugasti-Cruz; Jesús Antonio Morlett-Chávez; Luis Tlaloc Córdova-Alvelais Journal: Exp Ther Med Date: 2015-05-26 Impact factor: 2.447
Authors: Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio Journal: Adv Ther Date: 2015-10-26 Impact factor: 3.845